2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years

The pharmaceutical specialist has had strong momentum over the past six months, and that could continue for a while.Healthcare stocks have underperformed broader equities in recent years. But plenty of companies in the sector still look like good long-term bets.Take Regeneron Pharmaceuticals (REGN 1.90%), a biotech leader. Although it's faced its share of headwinds of late, the drugmaker could outperform the market through the next decade. Here are two potential reasons why. 1. Regeneron's main growth drive ...